Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
176 hedge funds and large institutions have $2.26B invested in Aerie Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 69 increasing their positions, 46 reducing their positions, and 19 closing their positions.
95% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 19
50% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 46
28% more capital invested
Capital invested by funds: $1.76B → $2.26B (+$490M)
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
23% more call options, than puts
Call options by funds: $6.61M | Put options by funds: $5.39M
10% more funds holding
Funds holding: 160 → 176 (+16)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$74.7M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$20.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$15.5M |
| 4 |
DCM
Daruma Capital Management
New York
|
+$12.4M |
| 5 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$68.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$51.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$39.2M |
| 4 |
O
OrbiMed
New York
|
-$35.8M |
| 5 |
CCI
Columbus Circle Investors
|
-$21.6M |
AERI Hedge Fund Activity: Q1 2019 in Review
176 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2019, worth a combined $2.26B — up 28% from $1.76B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AERI positions and 19 closed out — a net gain of 18 holders — while 69 added to existing stakes and 46 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $74.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $68.4M sold.
- 176 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2019, up from 160 in Q4 2018.
- Funds reported $2.26B of Aerie Pharmaceuticals stock for Q1 2019, up 28% quarter-over-quarter.
- 37 funds opened new Aerie Pharmaceuticals positions in Q1 2019 and 19 closed out, a net change of +18 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2019 was Consonance Capital Management, an estimated $74.7M added.
- The largest Aerie Pharmaceuticals seller in Q1 2019 was PFM Health Sciences, an estimated $68.4M sold.
Based on aggregated 13F filings for Q1 2019.